Is IBRX a good stock to buy now? We came across a bullish thesis on ImmunityBio, Inc. on r/pennystocks by Bailey-96. In this ...
Zacks Investment Research on MSN
Kyntra Bio (KYNB) upgraded to buy: Here's what you should know
Kyntra Bio (KYNB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...
Climb Bio, Inc. stays a Buy on budoprutug pMN data; Phase 2 PrisMN readout 2H 2026 + SLE/ITP upside and 2028 cash runway.
Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...
That morning, Belite announced that its leading drug candidate, tinlarebant, met its primary endpoint in a phase 3 trial. The medicine was being tested to determine its efficacy in treating ...
11dOpinion
Why ImmunityBio Stock Slumped on Monday
That regulator is the U.S. Food and Drug Administration (FDA). In mid-March, it sent ImmunityBio a warning letter stating ...
Q32 Bio on Monday sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics Inc. (NASDAQ: AKBA). ADX-097, the lead product candidate from Q32 Bio’s tissue-targeted complement inhibitor ...
Bio-Techne is set to announce its third-quarter earnings next month, and Wall Street expects the company’s EPS to decrease by ...
Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG) (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results